Vis enkel innførsel

dc.contributor.authorStoen, Maria J.
dc.contributor.authorAndersen, Sigve
dc.contributor.authorRakaee, Mehrdad
dc.contributor.authorPedersen, Mona I.
dc.contributor.authorIngebriktsen, Lise M.
dc.contributor.authorDønnem, Tom
dc.contributor.authorLombardi, Ana P. G.
dc.contributor.authorKilvaer, Thomas K.
dc.contributor.authorRasmussen Busund, Lill-Tove
dc.contributor.authorRichardsen, Elin
dc.date.accessioned2021-09-10T13:14:38Z
dc.date.available2021-09-10T13:14:38Z
dc.date.created2021-08-30T17:38:16Z
dc.date.issued2021
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/11250/2775250
dc.description.abstractObjective: assessing the prognostic role of miR-20a-5p, in terms of clinical outcome, in a large multi-institutional cohort study. Methods: Tissue microarrays from 535 patients’ prostatectomy specimens were constructed. In situ hybridization was performed to assess the expression level of miR-20a-5p in different tissue subregions: tumor stroma (TS) and tumor epithelium (TE). In vitro analysis was performed on prostate cancer cell lines. Results: A high miR-20a-5p expression was found negatively in association with biochemical failure in TE, TS and TE + TS (p = 0.001, p = 0.003 and p = 0.001, respectively). Multivariable analysis confirmed that high miR-20a-5p expression in TE independently predicts dismal prognosis for biochemical failure (HR = 1.56, 95% CI: 1.10–2.21, p = 0.014). Both DU145 and PC3 cells exhibited increased migration ability after transient overexpression of miR-20a-5p, as well as significant elevation of invasion in DU145 cells. Conclusion: A high miR-20a-5p expression in tumor epithelium is an independent negative predictor for biochemical prostate cancer recurrence.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleOverexpression of mir-20a-5p in tumor epithelium is an independent negative prognostic indicator in prostate cancer—a multi-institutional studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 the authorsen_US
dc.source.articlenumber4096en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3390/cancers13164096
dc.identifier.cristin1929866
dc.source.journalCancersen_US
dc.identifier.citationCancers. 2021, 13 (16), 4096.en_US
dc.source.volume13en_US
dc.source.issue16en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal